Innovotech Cash Flow per Share
Operating Cash Flow per Share of Innovotech (IOT.V) as of Nov 20, 2026.
Get this data via API
Financial Data API
Cash Flow per Share
-0.00CAD
YoY
-23.63%
Last updated:
Operating Cash Flow per Share of Innovotech is 2025 -0.00 CAD. Operating Cash Flow per Share of Innovotech was 2024 -0.00 CAD. It decreases by -23.63% higher compared to the previous year.
The Innovotech Cash Flow per Share history
3 Years
10 Years
25 Years
Max
Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2018
-0.01 CAD
Jan 1, 2019
0.00 CAD
Jan 1, 2020
0.00 CAD
Jan 1, 2021
0.00 CAD
Jan 1, 2022
0.01 CAD
Jan 1, 2023
-0.01 CAD
Jan 1, 2024
-0.00 CAD
Jan 1, 2025
-0.00 CAD
| YEAR | Cash Flow per Share | YoY |
|---|---|---|
| -0.00CAD | -23.63% | |
| -0.00CAD | -71.82% | |
| -0.01CAD | -209.25% | |
| 0.01CAD | +732.10% | |
| 0.00CAD | -85.94% | |
| 0.00CAD | +117.40% | |
| 0.00CAD | -126.54% | |
| -0.01CAD | +62.70% | |
| -0.00CAD | -6,127.90% | |
| 0.00CAD | -90.20% | |
| 0.00CAD | -146.61% | |
| -0.00CAD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Innovotech Stock analysis
What does Innovotech do? Innovotech Inc. generates revenue through the sale of proprietary assay kits, including MBEC Assay Kits, Order Biofilm Assays, and Coated MBEC Assay Lids, which are used in microbial biofilm research. The company also provides contract research services such as Antimicrobial Contract Research, Antimicrobial and Anti-Biofilm Agents testing (MIC and MBEC), and Customized Antimicrobial Testing (BEST Assay Testing and Implanted Medical Device Testing). Its antimicrobial silver products, AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products, are sold to customers in agricultural and medical sectors. The firm targets research institutions, agricultural producers, and medical device manufacturers seeking biofilm and antimicrobial testing solutions.
Innovotech's intellectual property portfolio supports its contract research services, which include testing for antimicrobial agents and materials under standards like TM100, ISO 22196, and USP 51. The company’s Biofilm Publications and SEM Library serve as additional resources for clients engaged in biofilm research. Its product offerings are tailored to sectors requiring microbial biofilm analysis, such as crop protection and medical device development, with AgreGuard-1 and InnovoSIL products specifically addressing antimicrobial needs in agriculture and medical applications.
The company monetizes its proprietary technology through direct sales of assay kits and antimicrobial silver products, while contract research services provide recurring revenue streams. Clients include research organizations conducting biofilm studies, agricultural businesses using AgreGuard-1 for crop protection, and medical device manufacturers utilizing InnovoSIL for antimicrobial properties. Innovotech’s focus on specialized testing methodologies and branded products ensures consistent demand from niche markets requiring precise biofilm and antimicrobial evaluation. Innovotech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Innovotech stock
On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Innovotech since 2006 – with annual values, charts, and detailed analysis.
Operating cash flow per share measures the operating cash generated per outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Innovotech
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Innovotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth